Background: There is increasing evidence that lncRNA, a type of transcript that is over 200 nucleotides
in length and may serve as oncogenes or suppressor genes, is implicated in the pathophysiology of human
diseases. In particular, tumorigenesis and progress are closely correlated with its abnormal expression. In addition,
it may become a promising target for many oncology biotherapies. Abnormal DLX6-AS1 expression affects
different cellular processes such as proliferation, aggression and metastasis. This review aims to probe into
the pathophysiological functions and molecular mechanisms of DLX6-AS1 in various cancers.
Methods: By retrieving the literature, this review summarizes the biological function and mechanism of
LncRNA DLX6-AS1 in tumor occurrence.
Results: The lncRNA DLX6-AS1 is a new tumor-related RNA that has recently been found to be aberrantly
expressed in diverse cancers, such as pancreatic cancer, osteosarcoma, non-small cell lung cancer, gastric carcinoma,
glioma, hepatocellular cancer, colorectal carcinoma, renal carcinoma, esophageal squamous cell cancer,
ovarian cancer, Ewing sarcoma, cervical cancer, breast cancer, thyroid cancer, neuroblastoma, pulmonary adenocarcinoma,
nasopharyngeal carcinoma, squamous laryngeal cancer and bladder cancer, etc. Meanwhile, it is
identified that DLX6-AS1 regulates the aggression, translocation and proliferation of diverse cancers.
Conclusion: LncRNA DLX6-AS1 may be viable markers in tumors or a potential therapeutic target for multiple